Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (121-130 of 1,111) with videos related to

Pageof 112
Sort By:
Archives of Cardiovascular Diseases|February 22, 2014
Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF SurveyHabib Gamra, Jan Murin, Chern-En Chiang, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 26, 2010
Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registryZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
European Heart Journal|March 9, 2013
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysisJonas Oldgren, Lars Wallentin, John H Alexander, et al.
Plos One|February 6, 2014
Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF surveyJan Murin, Lisa Naditch-Brûlé, Sandrine Brette, et al.
Atherosclerosis|February 17, 2026
In silico prediction of the lipid-lowering efficacy of the oral PCSK9 inhibitor enlicitide using a mechanistic computational modelBertrand Cariou, Yishu Wang, Denis Angoulvant, et al.
Cardiovascular Research|January 22, 2024
Do patients benefit from omega-3 fatty acids?Samuel C R Sherratt, R Preston Mason, Peter Libby, et al.
Heart (British Cardiac Society)|May 10, 2025
Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemiaGuillaume Roger, Chris J Packard, Luis Masana, et al.
International Journal of Cardiology|June 13, 2017
Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysisAnubodh Varshney, Ph Gabriel Steg, Yedid Elbez, et al.
Stroke|March 3, 2007
Autopsy prevalence of coronary atherosclerosis in patients with fatal strokeFernando Gongora-Rivera, Julien Labreuche, Arturo Jaramillo, et al.
Critical Pathways in Cardiology|August 22, 2022
International Perspectives on the Impact of the COVID-19 Pandemic on Adherence to Prescribed Dual Antiplatelet Therapy: A Window Into Acute Cardiovascular CareCharles V Pollack, P Gabriel Steg, Stefan James, et al.
Pageof 112

Showing results (121-130 of 1,111) with videos related to

Sort By:
Pageof 112
Archives of Cardiovascular Diseases|February 22, 2014
Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF SurveyHabib Gamra, Jan Murin, Chern-En Chiang, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 26, 2010
Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registryZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.
European Heart Journal|March 9, 2013
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysisJonas Oldgren, Lars Wallentin, John H Alexander, et al.
Plos One|February 6, 2014
Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF surveyJan Murin, Lisa Naditch-Brûlé, Sandrine Brette, et al.
Atherosclerosis|February 17, 2026
In silico prediction of the lipid-lowering efficacy of the oral PCSK9 inhibitor enlicitide using a mechanistic computational modelBertrand Cariou, Yishu Wang, Denis Angoulvant, et al.
Cardiovascular Research|January 22, 2024
Do patients benefit from omega-3 fatty acids?Samuel C R Sherratt, R Preston Mason, Peter Libby, et al.
Heart (British Cardiac Society)|May 10, 2025
Concept and practice in the use of high-dose eicosapentaenoic acid for cardiovascular disease prevention in hypertriglyceridaemiaGuillaume Roger, Chris J Packard, Luis Masana, et al.
International Journal of Cardiology|June 13, 2017
Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysisAnubodh Varshney, Ph Gabriel Steg, Yedid Elbez, et al.
Stroke|March 3, 2007
Autopsy prevalence of coronary atherosclerosis in patients with fatal strokeFernando Gongora-Rivera, Julien Labreuche, Arturo Jaramillo, et al.
Critical Pathways in Cardiology|August 22, 2022
International Perspectives on the Impact of the COVID-19 Pandemic on Adherence to Prescribed Dual Antiplatelet Therapy: A Window Into Acute Cardiovascular CareCharles V Pollack, P Gabriel Steg, Stefan James, et al.
Pageof 112